Pharmsintez reported for 2023 by RAS11.04.2024 at 18:31Vladimir PetenyovNews editorpress@blackterminal.comPharmsintez's RAS loss for 2023 amounted to ₽241.57 million, down 8.7% from ₽264.54 million in the previous year. Revenue declined 8% to ₽284.4 million from ₽309.09 million a year earlier.PharmsynthesLIFE2.39 ₽+1.70%ReviewSource: e-disclosure.ru